Mar-31-21 Initiated
BMO Capital Markets
Outperform
$101
Dec-14-20 Upgrade
Oppenheimer
Perform → Outperform
Jun-01-20 Upgrade
Citigroup
Neutral → Buy
$45
May-12-20 Initiated
Oppenheimer
Perform
Dec-19-19 Initiated
H.C. Wainwright
Buy
$50
Nov-25-19 Initiated
Guggenheim
Buy
$50
Oct-24-19 Upgrade
Goldman
Neutral → Buy
$23 → $38
Sep-25-19 Initiated
Wedbush
Outperform
$38
Sep-12-19 Initiated
BMO Capital Markets
Outperform
Aug-06-19 Initiated
Cantor Fitzgerald
Overweight
$42
Jun-05-19 Downgrade
Citigroup
Buy → Neutral
$21 → $22
Apr-12-19 Initiated
Evercore ISI
Outperform
Oct-22-18 Initiated
Piper Jaffray
Overweight
$23
Oct-22-18 Initiated
Goldman
Neutral
$17
Oct-22-18 Initiated
Citigroup
Buy
$21
Apr-12-21 02:28PM
Apr-05-21 04:30PM
Mar-10-21 04:30PM
Mar-01-21 08:15AM
07:59AM
07:00AM
Feb-18-21 12:01AM
Feb-08-21 04:30PM
Dec-28-20 04:30PM
Dec-23-20 04:40PM
Dec-16-20 01:37PM
Dec-15-20 08:35PM
07:48PM
09:48AM
09:17AM
Dec-14-20 04:37PM Investor's Business Daily +95.06%
04:06PM
01:50PM
09:48AM
07:00AM
Dec-11-20 04:15PM
Nov-25-20 07:00AM
Nov-16-20 09:21AM
Nov-07-20 07:43AM
Nov-05-20 07:00AM
05:52AM
Oct-14-20 07:00AM
Oct-06-20 05:17PM
Sep-15-20 11:42AM
Sep-04-20 07:00AM
Aug-07-20 07:00AM
Aug-04-20 09:05AM
07:00AM
Jul-30-20 08:45AM
Jul-27-20 12:31PM
Jul-20-20 12:15PM
Jun-29-20 04:30PM
Jun-17-20 07:00AM
Jun-15-20 09:48AM
Jun-11-20 07:00AM
Jun-05-20 12:00PM
07:00AM
May-29-20 10:28AM
07:00AM
May-20-20 04:30PM
May-14-20 12:33PM
May-13-20 05:49PM
May-12-20 08:54AM
May-05-20 12:00PM
May-01-20 06:33AM
Apr-28-20 09:37AM
08:35AM
07:00AM
Apr-18-20 10:02AM
Apr-13-20 04:54PM
Mar-31-20 07:00AM
06:27AM
Mar-20-20 11:30AM
Mar-19-20 08:56AM
Mar-18-20 06:52AM
Mar-16-20 08:15AM
07:00AM
Feb-17-20 12:00PM
Jan-31-20 09:31AM
Jan-29-20 06:51AM
Jan-17-20 05:37AM
Dec-19-19 06:27PM
Nov-27-19 07:30AM
Nov-26-19 08:06AM
Nov-25-19 11:40AM
Nov-21-19 07:30AM
Nov-17-19 12:44PM
Nov-06-19 09:40PM
04:01PM
Nov-05-19 09:00AM
Nov-04-19 05:00PM
Oct-31-19 11:50AM
Oct-30-19 09:36AM
Oct-23-19 07:54AM
06:30AM
Oct-20-19 08:08AM
Oct-19-19 09:02AM
Oct-17-19 07:00AM
Oct-02-19 07:00AM
Oct-01-19 02:54PM American City Business Journals -7.10%
04:00AM
Sep-25-19 02:44PM
Aug-27-19 07:00AM
Aug-16-19 12:46PM
Aug-07-19 07:00AM
Aug-05-19 07:00AM
Jul-31-19 01:48PM
Jul-29-19 07:00AM
Jul-25-19 07:00AM
Jul-18-19 07:00AM
Jun-27-19 06:54AM
Jun-26-19 06:28PM
Jun-25-19 07:00AM
Jun-20-19 08:30AM
Jun-06-19 07:00AM
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Taylor Ian Chief Scientific Officer Apr 05 Option Exercise 16.00 25,000 400,000 103,645 Apr 07 06:00 PM Taylor Ian Chief Scientific Officer Apr 05 Sale 66.81 25,000 1,670,143 78,645 Apr 07 06:00 PM Taylor Ian Chief Scientific Officer Mar 02 Sale 77.45 894 69,240 78,645 Mar 02 09:04 PM Cassidy Sean A Chief Financial Officer Mar 02 Sale 77.45 2,221 172,015 158,249 Mar 02 09:02 PM Houston John G President and CEO Mar 02 Sale 77.45 8,115 628,503 827,643 Mar 02 09:00 PM Taylor Ian Chief Scientific Officer Feb 19 Option Exercise 16.00 6,456 103,296 76,854 Feb 23 06:09 PM Cassidy Sean A Chief Financial Officer Feb 17 Option Exercise 16.00 894 14,304 155,678 Feb 18 05:16 PM Houston John G President and CEO Feb 16 Option Exercise 16.00 1,560 24,960 817,760 Feb 18 05:26 PM Peck Ronald Chief Medical Officer Feb 16 Option Exercise 26.58 20,000 531,600 22,754 Feb 18 05:05 PM Cassidy Sean A Chief Financial Officer Feb 16 Option Exercise 16.00 41,959 671,344 196,743 Feb 18 05:09 PM Houston John G President and CEO Feb 16 Option Exercise 16.00 44,000 704,000 860,000 Feb 18 05:11 PM Houston John G President and CEO Feb 16 Sale 78.79 44,000 3,466,601 816,200 Feb 18 05:11 PM Cassidy Sean A Chief Financial Officer Feb 16 Sale 78.46 41,959 3,292,108 154,784 Feb 18 05:09 PM Peck Ronald Chief Medical Officer Feb 16 Sale 77.35 20,000 1,546,992 2,754 Feb 18 05:05 PM Ratcliffe Liam Director Dec 18 Buy 70.00 142,857 9,999,990 822,857 Dec 21 06:00 PM Cassidy Sean A Chief Financial Officer Nov 09 Option Exercise 16.00 3,006 48,096 154,784 Nov 12 06:00 PM Kennedy Edward Moore Jr. Director Nov 09 Buy 23.99 8,333 199,909 42,718 Nov 12 06:05 PM Peck Ronald Chief Medical Officer Aug 14 Sale 27.46 1,256 34,490 2,754 Aug 18 07:00 PM SHANNON TIMOTHY M Director Jun 17 Buy 30.26 2,000 60,520 79,546 Jun 19 05:00 PM SHANNON TIMOTHY M Director Jun 02 Buy 32.30 3,000 96,900 77,546 Jun 04 09:00 PM SHANNON TIMOTHY M Director May 26 Option Exercise 22.06 12,923 285,081 74,546 May 26 07:05 PM Ratcliffe Liam Director May 26 Option Exercise 22.06 6,500 143,390 6,500 May 27 06:34 PM Cassidy Sean A Chief Financial Officer May 13 Option Exercise 16.00 1,356 21,696 151,778 May 14 09:30 PM Cassidy Sean A Chief Financial Officer May 12 Sale 60.00 10,000 600,000 150,422 May 14 09:25 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite